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ABSTRACT
Esophageal squamous cell carcinoma (ESCC) in humans is a deadly disease
associated with dietary zinc (Zn)-deficiency. In the rat esophagus, Zn-deficiency
induces cell proliferation, alters mRNA and microRNA gene expression, and promotes
ESCC. We investigated whether Zn-deficiency alters cell metabolism by evaluating
metabolomic profiles of esophageal epithelia from Zn-deficient and replenished
rats vs sufficient rats, using untargeted gas chromatography time-of-flight mass
spectrometry (n = 8/group). The Zn-deficient proliferative esophagus exhibits a
distinct metabolic profile with glucose down 153-fold and lactic acid up 1.7-fold (P
< 0.0001), indicating aerobic glycolysis (the “Warburg effect”), a hallmark of cancer
cells. Zn-replenishment rapidly increases glucose content, restores deregulated
metabolites to control levels, and reverses the hyperplastic phenotype. Integration
of metabolomics and our reported transcriptomic data for this tissue unveils a link
between glucose down-regulation and overexpression of HK2, an enzyme that
catalyzes the first step of glycolysis and is overexpressed in cancer cells. Searching
our published microRNA profile, we find that the tumor-suppressor miR-143, a
negative regulator of HK2, is down-regulated in Zn-deficient esophagus. Using in
situ hybridization and immunohistochemical analysis, the inverse correlation between
miR-143 down-regulation and HK2 overexpression is documented in hyperplastic Zndeficient esophagus, archived ESCC-bearing Zn-deficient esophagus, and human ESCC
tissues. Thus, to sustain uncontrolled cell proliferation, Zn-deficiency reprograms
glucose metabolism by modulating expression of miR-143 and its target HK2. Our work
provides new insight into critical roles of Zn in ESCC development and prevention.
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INTRODUCTION

miRNA expression levels are altered in all human cancers
studied, including ESCC [21], can act as oncogenes
or tumor suppressors [22, 23] and have emerged as
therapeutic targets for cancer [24]. Using the NanoString
microRNA expression profiling platform, we showed that
ZD promotes ESCC by inducing an oncogenic miRNA
signature that resembles the human ESCC miRNAome
[25] with up-regulation of oncogenic miR-31, -223, and
-21 [26-28]. Additionally, ESCC development and the
underlying miRNA dysregulation are dependent on the
extent of dietary deficiency of Zn [28].
In the early 1920s, Warburg discovered that unlike
normal tissues, tumor cells convert glucose to lactate
even under aerobic condition, establishing that cancer
cells exhibit altered cellular metabolism fundamental
to carcinogenesis [29, 30]. In the ensuing years, this
phenomenon of aerobic glycolysis or Warburg effect
has been documented in a variety of human cancers,
including ESCC [31], most readily by assessing glucose
uptake using positron emission tomography (PET) with a
radiolabeled analog of glucose (118F-fuorodeoxyglucose,
FDG) as reporter. Altered metabolism is now considered a
hallmark of cancer [14], and deregulated uptake of glucose
is a common feature of cancer-associated metabolic
changes [32].
Given that altered metabolism results from
active reprogramming by altered oncogenes and
tumor suppressors [33], these metabolite changes are
downstream and complementary to changes in genes
and proteins and are key players in biological networks.
Additionally, miRNAs have emerged as key regulators of
cellular metabolism in normal and pathological conditions
[34]. For example, miR-122 and its host gene regulate
cholesterol and lipid metabolism in liver [35]; miR-143
and its target gene, HK2, regulates aerobic glycolysis in
tumor cells [36-39].
We hypothesized that in addition to inducing a
hyperplastic esophageal phenotype along with oncogenic
alterations in mRNA and miRNA gene expression,
dietary ZD also causes altered cellular metabolism during
early esophageal carcinogenesis. To investigate this,
we performed untargeted metabolomic profiling by gas
chromatography time-of-flight mass spectrometry (GCTOF MS) to evaluate metabolite changes in esophageal
mucosa obtained from ZD rats vs ZS rats [16]. GC-TOF
MS based metabolic profiling has been used for studying
primary metabolism (sugars, lipids, & small peptides) in
the characterization of human cancers such as ovarian
carcinoma [40, 41] and lung adenocarcinoma [42-44].
To gain insights into the molecular basis of alterations in
biochemical pathways, we integrated metabolomics of
ZD rat esophagus with our reported transcriptome dataset
for this tissue from a study of identical design [16]. We
also investigated whether a miRNA-mRNA-metabolite
network can be established in early ZD-associated
esophageal tumor development by searching our reported
miRNA profile data [28].

Although cancer mortality rates have declined
worldwide since the mid 1980s, esophageal squamous cell
carcinoma (ESCC), the predominant esophageal cancer
subtype, has a 5-year survival of only 10% [1]. Due to
lack of early symptoms, ESCC is typically diagnosed
at an advanced stage that defies treatment by surgery
combined with radio/chemotherapy. Thus, clarification of
the mechanisms underlying the pathogenesis of ESCC and
development of new prevention and therapeutic strategies
are critically needed.
Zinc (Zn)-deficiency (ZD) is recognized as a major
worldwide public health problem [2-6], affecting ~31%
of the global population with higher rates in developing
countries [5]. Although severe ZD is uncommon, mildto-moderate ZD is prevalent throughout the world [7].
Epidemiologic and clinical studies have implicated dietary
ZD in the etiology of ESCC [8-10]. Specifically, Abnet
et al. [11] demonstrated that tissue Zn concentration
is inversely associated with the subsequent risk of
developing ESCC. Because Zn is required for the activity
of hundreds of enzymes, for proper immune function,
and for the conformation of > 2000 transcription factors
that control cell proliferation, apoptosis, and signaling
pathways [12, 13], ZD predisposes to disease by adversely
affecting many processes.
Cell proliferation is a hall mark of cancer [14].
Previously, we showed that rats on a ZD diet for ~6
weeks develop a hyperplastic esophagus with sustained,
uncontrolled cell proliferation [15]. In transcriptome
analyses using DNA microarrays, the ZD esophagus
showed a distinct gene expression signature with the
proinflammation mediators S100a8/a9 as the top upregulated genes [16]. Zn-replenishment (ZR) rapidly
restored to control levels the expression of S100A8/A9
and other genes and reversed the hyperplastic phenotype
[16]. In addition, prolonged ZD (21 weeks) leads to an
expanded cancer-associated inflammatory program that
when combined with non-carcinogenic low doses of the
environmental carcinogen N-nitrosomethylbenzylamine
(NMBA), elicited a 67% incidence of ESCC [17]. Among
the up-regulated genes were genes known as hallmarks
of cancer-related inflammation (chemokines, cytokines,
prostaglandins) implicated in the development of human
cancers, including ESCC [18, 19]. Again, ZR reversed
this inflammatory gene signature and prevented cancer
formation [17, 20]. Thus, our ZD rat esophageal cancer
model reproduces the path to human ESCC and provides
an opportunity to understand the molecular basis of ESCC
associated with ZD.
MicroRNAs (miRNA) are short non-coding RNAs
that regulate gene expression by translational inhibition
and mRNA degradation. Individual miRNAs can inhibit
multiple target genes or entire signaling pathways,
including cell proliferation, differentiation, and apoptosis.
www.impactjournals.com/oncotarget
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RESULTS

Metabolic profile of hyperplastic ZD esophagus
Metabolomic analysis by GC-TOF MS in
esophageal mucosa from ZD and ZS rats (n = 8 per group)
yielded a total of 353 compounds, of these 155 were
structurally known metabolites and 198 were unknown
compounds. Using a cutoff point of P value < 0.05 and
≥ 1.3-fold difference, the proliferative ZD esophagus
exhibited a distinct metabolic signature as compared with
its non-proliferative ZS counterpart. A total of 71 known
metabolites were significantly altered, with 27 metabolites
down-regulated and 44 up-regulated (Table 1). To display
the biochemical differences between hyperplastic ZD and
control ZS esophagus, a metabolomic network [45] was
calculated among the structurally identified metabolites
using the Kyoto encyclopedia of genes and genomes
(KEGG ) databases [46] and PubChem CIDs identifiers
[47] (Figure 1).
Of the 27 metabolites that were significantly downregulated in the hyperplastic ZD esophagus, sixteen

Esophageal mucosa samples for GC-TOF MSbased analysis
Esophageal mucosa samples were obtained from
Zn-modulated rats after a 6-week dietary regimen as
described before [16]. Consistent with previous studies
[15, 16, 20], the Zn status marker, testis Zn content (µg/g
dry weight, mean ± SD), was significantly lower in ZD
than control ZS rats (105 ± 18 vs 131 ± 6.8, P < 0.01, n
= 8 rats/group). Also, the ZD esophagus was hyperplastic
with a high rate of cell proliferation, as compared with ZS
esophagus that is typically 2 to 3 cells thick. Seventy-two
hours after replenishing Zn, testis zinc content in ZR rats
was 139 ± 11 µg/g dry weight, a result comparable to ZS
rats. At the same time, ZR esophagus reverted to a near
normal esophageal phenotype, consistent with previous
studies [16, 20].

Figure 1: Metabolomic network of biochemical differences between hyperplastic Zn-deficient and Zn-sufficient
esophagus. Each node represents an identified metabolite. Metabolites are connected based on biochemical relationships (red, KEGG

RPAIRS) or structural similarity (light blue, Tanimoto coefficient ≥ 0.7). Metabolite size reflects fold-change (ZD vs ZS); node color
represents relative change (Blue, decrease, P < 0.05; Red, increase, P < 0.05; yellow, insignificant change) metabolite size reflects absolute
fold change (Table 1). Labels are shown for the metabolites that pass the significance cutoff (P < 0.05)
www.impactjournals.com/oncotarget
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Table 1: Metabolomic signature in precancerous Zn-deficient rat esophagus
Fold change (ZD vs
ZS)

P-value

glucose

-153

0.0002

Glycolysis/gluconeogenesis

maltose

-20

0.0002

Starch & sucrose metabolism

maltotriose

-9.0

0.0002

ATP-binding cassette transporters

glucose-6-phosphate

-8.8

0.0011

Glycolysis/pentose phosphate pathway

mannose

-7.5

0.0011

Fructose & mannose metabolism

3,6-anhydro-D-galactose

-6.7

0.0100

---

ascorbic acid

-6.1

0.0009

Glutathione metabolism

1-monoolein

-5.9

0.0002

---

citric acid

-5.3

0.0003

Citrate cycle (TCA Cycle)

pentadecanoic acid

-5.1

0.0002

---

hexitol

-3.6

0.0002

Fructose & mannose metabolism

beta-glutamic acid

-3.4

0.0022

---

fructose

-3.4

0.0002

Starch & sucrose metabolism

phosphoenolpyruvate

-3.3

0.0017

Glycolysis/gluconeogenesis

myo-inositol

-2.9

0.0001

Galactose Metabolism

sulfuric acid

-2.9

0.0012

Purine metabolism

isoheptadecanoic acid NIST

-2.9

0.0150

---

beta-sitosterol

-2.8

0.0001

Steroid biosynthesis

threonic acid

-2.4

0.0018

Ascorbate & aldarate metabolism

inosine

-2.3

0.0370

Purine metabolism

1,5-anhydroglucitol

-2.2

0.0002

---

sorbitol

-2.1

0.0019

Fructose & mannose metabolism

hexuronic acid

-2.0

0.0003

---

raffinose

-1.9

0.0027

Galactose metabolism

aspartic acid

-1.8

0.0415

Amino acid metabolism

taurine

-1.7

0.0019

Primary bile acid metabolism

glycerol

-1.4

0.0085

Galactose/glycerolipid metabolism

putrescine

14

0.0100

Glutathione/amino acid metabolism

hexadecylglycerol NIST

10

0.0002

---

inosine 5'-monophosphate

6.4

0.0063

Purine metabolism

indole-3-lactate

5.5

0.0140

Tryptophan degradation

cytidine-5-monophosphate
NIST

4.7

0.0013

Pyrimidine metabolism

zymosterol

3.7

0.0000

---

alpha-ketoglutarate

3.5

0.0380

---

cytosine

3.3

0.0002

Pyrimidine metabolism

adenosine-5-monophosphate

3.0

0.0011

Purine metabolism

pseudo uridine

3.0

0.0100

Pyrimidine metabolism

cytidine

2.6

0.0003

Pyrimidine metabolism

cysteine

2.4

0.0000

Amino acid metabolism

octadecylglycerol

2.4

0.0030

---

Metabolite name

Biological process

27 down-regulated

44 up-regulated
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uric acid

2.3

0.0100

Purine metabolism

succinic acid

2.2

0.0070

Citrate cycle (TCA cycle)

thymidine

2.1

0.0047

Pyrimidine metabolism

maleimide

2.1

0.0067

---

2-ketoisocaproic acid

2.1

0.0149

Amino acid metabolism

palmitoleic acid

2.1

0.0030

Fatty acid biosynthesis

4-hydroxybutyric acid

2.1

0.0000

Butanoate metabolism

pyrophosphate

2.0

0.0043

Oxidative phosphorylation

behenic acid

2.0

0.0002

Biosynthesis of unsaturated fatty acids

aminomalonate

1.8

0.0100

---

beta-alanine

1.8

0.0402

Pyrimidine metabolism

UDP-N-acetylglucosamine

1.8

0.0047

Amino sugar & nucleotide sugar metabolism

arachidic acid

1.7

0.0001

Biosynthesis of unsaturated fatty acids

lactic acid

1.7

0.0000

Glycolysis, pyruvate metabolism

alanine-alanine

1.7

0.0011

D-alanine metabolism

ethanolamine

1.7

0.0001

---

xylitol

1.6

0.0380

Riboflavin metabolism

lignoceric acid

1.6

0.0044

Biosynthesis of unsaturated fatty acids

phosphate

1.6

0.0037

Oxidative phosphorylation

arachidonic acid

1.6

0.0150

Biosynthesis of unsaturated fatty acids

proline

1.5

0.0124

Amino acid metabolism

phosphoethanolamine

1.5

0.0438

Glyerophospholipid metabolism

uracil

1.5

0.0395

Pyrimidine metabolism

glutamine

1.4

0.0148

Amino acid metabolism C/N balance

phenylalanine

1.4

0.0132

Amino acid metabolism

serine

1.4

0.0000

Amino acid metabolism

alanine

1.3

0.030

Amino acid metabolism

glutamic acid

1.3

0.001

Amino acid metabolism

nicotinamide

1.3

0.021

Energy metabolism

threonine

1.3

0.009

Amino acid metabolism

glycine

1.3

0.001

Amino acid metabolism

A group of 71 significantly altered metabolites were identified in ZD vs ZS esophagus using a cutoff point of P-value ≤5% and
fold-change ≥1.3 (n = 8 rats/cohort). ZD = Zn-deficient; ZS = Zn-sufficient.
(59%) were carbohydrates, including glucose, glucose-6phosphate, maltose, maltotriose, mannose, 3,6-anhydroD-galactose, and fructose. The remaining 41% were
lipids (three), amino acids (three), nucleotide (one), sterol
(one), organic acid (one), and others (two) (Figure 1
and Table 1). Most strikingly, glucose was decreased by
153-fold (P < 0.001). Glucose depletion was positively
correlated with a 1.7-fold increase in lactic acid (P <
0.001). This result indicates that the proliferating ZDesophageal cells vigorously consume glucose (resulting in
glucose depletion), and produce lactic acid under aerobic
conditions.
Because of the need to replicate all of its cellular
contents, proliferating cells have a high biosynthetic
www.impactjournals.com/oncotarget

demand for amino acids, lipids, and nucleotides. Thus, in
cancer cells aerobic glycolysis fulfills the requirement to
support cell proliferation rather than to generate energy
in the form of adenosine 5’-triphosphate (ATP) [48]. The
highly proliferative ZD esophagus showed a metabolic
profile consistent with uncontrolled proliferation. Of
the 44 up-regulated metabolites (Table 1 and Figure
1), many were involved in amino acid metabolism/
protein biosynthesis (putrescine, cysteine, beta-alanine,
ethanolamine, proline, glutamine, phenylalanine,
nicotinamide etc.), purine & pyrimidine metabolism
(inosine 5’-monophosphate, cytidine-5-monophosphate,
adenosine-5-monophosphate, cytidine, uric acid,
thymidine, phosphate), unsaturated fatty acids biosynthesis
81914

Oncotarget

Table 2: Metabolomic profiling of esophageal mucosa from Zn-replenished rats at 72 hours after Zn-replenishment
as compared to Zn-sufficient counterpart
Metabolite name

Fold change (ZR vs ZS)

P-value

Biological process

13 down-regulated
glucose

-20

0.0006

Glycolysis/gluconeogenesis

pentadecanoic acid

-5.8

0.0002

---

3,6-anhydro-D-galactose

-3.7

0.0100

ATP-binding cassette transporters

maltose

-3.1

0.0104

Starch & sucrose metabolism

sorbitol

-3.0

0.0002

Fructose & mannose metabolism

linoleic acid

-2.2

0.0171

Biosynthesis of prostaglandin

beta-glutamic acid

-1.9

0.0371

---

isoheptadecanoic acid NIST

-1.9

0.0210

---

fumaric acid

-1.7

0.0100

Citrate cycle (TCA cycle)

hexuronic acid

-1.6

0.0135

---

1,5-anhydroglucitol

-1.5

0.0047

---

beta-sitosterol

-1.5

0.0361

Steroid biosynthesis

N-acetylmannosamine

-1.4

0.0348

Amino/nucleotide sugar metabolism

indole-3-lactate

2.8

0.0031

Tryptophan degradation

ornithine

2.2

0.0463

Arginine biosynthesis

tyrosine

2.0

0.0003

Amino acid metabolism

proline

1.7

0.0010

Amino acid metabolism

aminomalonate

1.7

0.0100

---

citrulline

1.7

0.0011

Arginine biosynthesis

alanine-alanine

1.7

0.0011

D-alanine metabolism

leucine

1.7

0.0004

Amino acid metabolism

oxoproline

1.6

0.0002

---

phenylalanine

1.6

0.0005

Amino acid metabolism

isoleucine

1.6

0.0002

Amino acid metabolism

valine

1.6

0.0002

Amino acid metabolism

methionine sulfoxide

1.5

0.0054

---

trans-4-hydroxyproline

1.5

0.0108

Amino acid metabolism

glutamine

1.5

0.0047

Amino acid metabolism C/N balance

glycine

1.4

0.0000

Amino acid metabolism

threonine

1.4

0.0023

Amino acid metabolism

17 up-regulated

A group of 30 significantly altered metabolites were identified in ZR vs ZS esophagus using a cutoff point of P-value ≤5%
and fold-change ≥1.3 (n = 8 rats/cohort). ZR = Zn-replenished; ZS = Zn-sufficient
(hexadecylglycerol, octadecylglycerol, arachidonic
acid, palmitoleic acid, arachidic acid), glycolysis (lactic
acid), and energy metabolism (nicotinamide). Of these,
the top up-regulated metabolite was the amino-acid
derived putrescine (up 14-fold, P < 0.01). High levels
of polyamines, including putrescine, are associated
with human cancers and cell proliferation through DNA
packaging [49, 50]. In summary, untargeted metabolomic
profiling by GC-TOF MS revealed that the proliferative
ZD esophageal mucosa exhibits extensive remodeling of
www.impactjournals.com/oncotarget

metabolism, including a high rate of aerobic glycolysis
accompanied by up-regulation of many metabolites that
serve as building blocks for biomass synthesis.

Reversal of cancer-associated metabolic profile by
ZR
To investigate the metabolic response following
Zn replenishment, we performed metabolomic analysis
81915
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by GC-TOF MS in restored esophageal mucosa from
ZR rats at 72 hours after replenishing Zn (n = 8 rats). As
shown Table 2, the number of significantly deregulated
metabolites in ZR vs ZS esophagus was 30 (13 downregulated & 17 up-regulated), which is ~42% of that in
ZD vs ZS esophagus (Table 1). In particular, glucose
deregulation was improved from a down-regulation of
153-fold in ZD esophagus to 20-fold in ZR counterpart
(P < 0.001, Table 2), as compared to ZS esophagus.
Putrescine, the top-up-regulated metabolite in ZD
esophagus was returned to ZS status. These metabolomic
results mirror those of transcriptomic data, in which,
shortly after ZR the altered gene expression rapidly
reverted to near control ZS levels, accompanied by
reduced cell proliferation, increased apoptosis, and a
reversal of the hyperplastic esophageal phenotype [16, 17,
20].

transcriptomics of ZD esophagus from a study of identical
design [16]. Previous microarray analysis by Affymetrix
rat genome 230 2.0 GeneChip identified a total of 2305
significantly deregulated genes in the hyperplastic ZD vs
ZS esophagus (fold change ≥ 2) from rats after a 6-week
dietary regimen [16]. A gene-metabolite integration
network (Supplementary Figure 1) was calculated by
queries in ZD vs ZS esophagus from the 2,305 deregulated
genes [16] and 71 significantly deregulated metabolites
(Table 1) and mapping with log2 fold-change using the
GRINN database within the metabox toolbox [51]. Several
metabolic pathways showed significant alterations at both
the transcriptional and metabolic levels (Supplementary
Figure 1). As examples, connections that occur between
specific gene and metabolite were observed between Hk2
up-regulation & glucose down-regulation; cytochrome
P450 genes (Cyp4b1, Cyp4f6, Cyp2a1) down-regulation
& arachidonic acid up-regulation; Atp2a2, Atp1a2
down-regulation/Atp7a, Dusp1, Pfkfb3 up-regulation &
phosphate (O4P-3) up-regulation; Gfpt2 down-regulation
& L-glutamine/L-glutamic acid up-regulation.
We focused our study on HK2-glucose link because
of its critical role in cancer metabolism [32]. Strikingly,
HK2 that was up-regulated 3.9-fold in hyperplastic ZD vs

Integration of metabolomics, transcriptomics, and
miRNA profiling dataset
To identify a key deregulated biochemical and
molecular signaling network in ZD-induced esophageal
preneoplasia, we integrated metabolomics with

Figure 2: Gene-metabolite integration network in Zn-deficient versus Zn-sufficient esophagus reveals a direct
connection between Hk2 up-regulation and decreased level of glucose metabolite. Biological relationship - blue, enzymatic
transformation; green, encoding gene. Node shape represents metabolite, protein, or gene. Node color represents fold change (ZD vs ZS)
and P < 0.05.
www.impactjournals.com/oncotarget
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Figure 3: Analysis of cell proliferation, miR-143 and HK2 expression in Zn-deficient preneoplastic and neoplastic rat
esophageal tissues. A. qPCR analysis of miR-143 (U87 as normalizer, n = 8 rats/group; results are shown as means, error bars represent

standard deviation). B. qPCR analysis of mRNA expression of HK2 (Psmb6 as normalizer, n = 8 rats/group; results are shown as means,
error bars represent standard deviation). Analysis of miR-143 and HK2 expression by in situ hybridization (ISH) and immunohistochemistry
(IHC) in formalin fixed paraffin embedded esophageal samples in - C. ZD versus ZS esophagus after a 6-week dietary regimen (n =
8 rats/group) D. Archived samples of ESCC-bearing ZD esophagus versus tumor-free control ZS esophagus [28] (n = 10 rats/group).
Representative hematoxylin and eosin [H&E]-stained and PCNA-stained sections are shown. miR-143 ISH signal (blue, 4-nitro-blue
tetrazolium and 5-brom-4-chloro-3′-indolylphosphate; counterstain, nuclear fast red). HK2 expression (brown, 3,3′-diaminobenzidine
tetrahydrochloride, counterstain, Harris modified hematoxylin). Scale bars: 50 μm (x200 magnification), 100 μm (x100 magnification, and
25 μm (x400 magnification, inset).
www.impactjournals.com/oncotarget
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Divergent inverse correlation of miR-143 &
HK2 expression in nonproliferative esophagus vs
proliferative ZD esophageal neoplasia and human
ESCC

ZS esophagus by microarray expression analysis [16] was
directly connected to down-regulated glucose metabolites,
namely, alpha-D-glucose and beta-D-glucose (Figure 2).
The HK2 enzyme catalyzes the first committed step in
glucose metabolism where glucose is phosphorylated to
yield glucose-6-phosphate. In mammals there are four
hexokinase isoforms, HK1, HK2, HK3, and HK4 (also
known as glucokinase). Only HK2 is expressed at high
levels in cancer cells [52, 53], thus accounting for the high
glycolytic rate in cancer cells [54]. Thus, by combining
metabolomics and transcriptomics, we have identified an
aerobic glycolysis network that involves HK2 and glucose
signaling associated with uncontrolled cell proliferation in
early esophageal cancer development induced by dietary
ZD.
Using the NanoString miRNA expression profiling
platform, we previously reported that prolonged ZD
(22 weeks) induced extensive alterations in miRNA
expression in the hyperplastic ZD esophagus, and many of
the dysregulated miRNAs are similarly altered in human
ESCC [28]. In a search for known miRNAs that regulate
HK2, we examined this published miRNA profiling data
for ZD esophagus [28]. Significantly, miR-143, a tumor
suppressor in human cancers, including ESCC [55, 56],
and a known negative regulator of HK2 [36], was downregulated 1.8-fold (P = 0.0136) in the highly proliferative
ZD esophagus as compared to its non-proliferative
counterpart vs ZS [28]. Based on this observation, we
went on to perform Taqman miRNA assays using qPCR
and showed that the tumor suppressor miR-143 was downregulated 2.5-fold in hyperplastic ZD vs ZS esophagus
from rats after a brief 6-week dietary regimen (P < 0.05, n
= 8 rats/group), and down-regulated 10-fold (P < 0.001, n
= 8 rats/group) in archived samples of ESCC-bearing ZD
esophagus vs non-ESCC-bearing ZS counterpart from an
esophageal tumor study in Zn-modulated rats [28]. In an
inverse manner, qPCR analysis showed that Hk2 mRNA
levels were significantly up-regulated in these same ZD
tissues (up 5.8-fold in hyperplastic ZD vs ZS esophagus
& up 5.4-fold in archived samples [28] of ESCC-bearing
ZD esophagus vs non-ESCC-bearing ZS esophagus (P <
0.01 to P < 0.001, n = 8 rats/group) (Figure 3B). Thus,
integration of metabolomics with transcriptomics [16]
& microRNA profiling data [28] in the hyperplastic ZD
esophagus revealed that deregulated glucose uptake
is accompanied by miR-143 down-regulation and upregulation of the hexokinase gene Hk2. This result is
consistent with reports that miR-143 is an essential
regulator of cancer glycolysis by targeting HK2 in cancer
cells, including lung cancer, head and neck squamous cell
carcinoma, renal cell carcinoma, and colon cancer cells
[36-39].

www.impactjournals.com/oncotarget

To understand the distribution and localization
of miR-143 in esophageal neoplasia in relation to
localization of its target HK2 protein and the level of cell
proliferation, we performed in situ hybridization (ISH)
and immunohistochemical staining (IHC) on near serial
sections of rat esophageal tissues (n = 10 rats/group), as
well as in the archived human ESCC tissues for which
we previously reported overexpression of miR-31, -21,
-223 [27, 28]. Cellular origin of miR-143 was defined by
ISH using high affinity double Dig-labeled LNA probes
(Exiqon, Vedbaek, Denmark). Localization of HK2
protein and the cell proliferation marker PCNA [56] were
evaluated by IHC.
Both nonproliferative ZS esophagus (after a
6-week dietary regimen) and non-ESCC-bearing ZS rat
esophagus (from an esophageal tumor study) showed
few PCNA-positive nuclei, mostly restricted to basal
cell layer (Figure 3C and 3D). Concurrently, these ZS
tissues showed abundant and intense miR-143 ISH signal
in basal and suprabasal cell layers along with weak HK2
protein expression. This finding indicates that robust
expression of this miRNA suppresses HK2 expression,
effects that support normal cell growth. By contrast, the
highly proliferative preneoplastic ZD esophagus, as well
as ESCC-bearing ZD esophagus displayed a high rate of
cell proliferation with abundant PCNA-positive nuclei in
many cell layers. At the same time, both preneoplastic
and cancerous phenotypes exhibited weak/diffuse
miR-143 ISH signals but moderate/strong cytoplasmic
HK2 expression (Figure 3C and 3D), indicating downregulation of the tumor suppressor, miR-143, leads to
overexpression of HK2 and enhanced cell proliferation/
ESCC development. Together, these data revealed for the
first time the opposing inverse-correlation between miR143 & HK2 expression in normal esophagus with limited
cell growth (ZS esophagus) and precancerous/cancerous
ZD esophageal cells with unbridled cell proliferation.
Using the same human ESCC tissues in which we
previously documented overexpression of miR-31, miR21, miR-223 by ISH [28], Figure 4 shows these human
ESCC tissues were also highly proliferative with numerous
PCNA-positive nuclei (n = 12 cases). While miR-143
ISH signals were absent in human ESCC tissues, strong
cytoplasmic HK2 protein expression was present (Figure
4). This result is typical of all 12 patients studied and is
consistent with that in the ZD preneoplastic/cancerous
esophageal tissues.
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Figure 4: Analysis of cell proliferation, miR-143 and HK2 expression in human esophageal squamous cell carcinoma
(ESCC) tissue by in situ hybridization and immunohistochemistry. Representative hematoxylin and eosin [H&E]-stained
and PCNA-stained ESCC tissues (2 cases are shown). miR-143 ISH signal (blue, 4-nitro-blue tetrazolium and 5-brom-4-chloro-3′indolylphosphate; counterstain, nuclear fast red) was absent in ESCC tumor area. HK2 expression (brown, 3,3′-diaminobenzidine
tetrahydrochloride) was moderate to strong in near serial formalin-fixed, paraffin-embedded sections of ESCC tumor tissue (Case 1 & 2).
Scale bars: 50 μm (x200 magnification), and 25 μm (x400 magnification, inset) (n = 12 cases).
www.impactjournals.com/oncotarget
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DISCUSSION

a role of HK2 in tumor initiation [58]. In patients with
ESCC, a positive correlation is well established between
a high 18F-FDG uptake (a marker for tissue uptake of
glucose) and HK2 activity in resected specimen [59, 60].
Thus, our finding of a HK2-glucose link in hyperplastic
ZD esophagus highlights the critical role of HK2 in
deregulated glucose metabolism in early esophageal tumor
development by ZD.
It is now well recognized that miRNAs play a
critical role in regulating cellular metabolism in health
and disease, including cancer, thereby generating a
bidirectional functional link in the crosstalk between
miRNA and metabolism [34, 61]. The most pronounced
metabolic alteration in cancer cells is deregulated uptake of
glucose and associated aerobic glycolysis [14, 32]. Critical
to cancer aerobic glycolysis is the glycolytic enzyme HK2
that catalyzes the first committed step in glycolysis [54].
In this study, integrated analysis of -omics datasets with
miRNA expression profiling revealed a miR-143-HK2glucose link in hyperplastic ZD esophagus. Moreover, we
showed that miR-143 regulates cancer glycolysis in ZDinduced esophageal neoplasia by targeting HK2 (Figure
3), a result consistent with reports for lung cancer, renal
cell carcinoma, head and neck squamous cell carcinoma,
breast cancer, and prostate cancer [36-38, 62, 63].
A limitation of this current study is the fact that
only the HK2-glucose gene-metabolite network is
studied in detail. Future studies are needed to investigate
other gene-metabolite connections in our integrated
analysis of metabolomics and transcriptomics (Figure 2,
Supplementary Figure 1). In addition, future studies are
needed to unravel the mechanism(s) whereby dietary ZD
regulates the expression of miR-143.
In summary, our metabolomic profiling reveals that
increased consumption of glucose is the most prominent
metabolic alteration in the highly proliferative ZD
esophagus. The finding that ZR rapidly corrects aberrant
metabolite levels, including that of glucose, indicates that
Zn regulates glucose metabolism in esophageal cancer
initiation and reversal. Integration of metabolomics with
our published transcriptomics and microRNA profiling
data revealed a miR-143-HK2-glucose pathway that
underlies esophageal neoplasia by ZD. The finding shows
that to support cell proliferation, ZD reprograms glucose
metabolism by modulating the expression of miR-143,
which targets HK2. Altogether, our data advance the
understanding of the mechanistic role of Zn in ESCC
development and prevention.

In the current study, untargeted metabolomic
profiling by GC-TOF MS showed that the highly
proliferative ZD rat esophagus has a distinct cancerassociated metabolomic signature as compared with
nonproliferative ZS counterpart (Table 1). Glucose downregulation (153-fold, P < 0.001) was accompanied by
up-regulation of lactic acid (1.7-fold, P < 0.001), a result
indicating a high rate of aerobic glycolysis (the Warburg
effect), a common feature of cancer cell metabolism.
At the same time, almost all of the 44 metabolites that
were up-regulated were intermediate precursors needed
for amino acid metabolism/protein biosynthesis, purine
& pyrimidine metabolism, or lipid biosynthesis. These
finding emphasize the requirement of cell proliferation to
provide building blocks to support de novo biosynthesis
needed to produce new cells [48]. Importantly, the
dysregulated metabolites, including glucose, were highly
Zn-responsive. Zn-replenishment rapidly increased
glucose content and restored many deregulated metabolites
to control levels (Table 2), accompanied by reversal of the
hyperplastic phenotype. Taken together, the metabolomic
data establish for the first time that the nutrient, Zn,
regulates cancer metabolism in esophageal neoplasia
development and reversal. This result is consistent with
the ZR effect on the reversal of altered gene expression in
esophageal neoplasia [16, 17].
To date, there are only a few metabolomic profiling
studies in human ESCC; most of which were performed on
biofluids from ESCC patients (plasma, serum, and urine).
Only one study was conducted on human ESCC tissues
vs normal mucosae using nuclear magnetic resonance,
where glucose down-regulation and up-regulation of
short-chain fatty acid were correlated with the stage of
ESCC [57], consistent with our metabolomic profile of the
preneoplastic rat esophagus induced by ZD.
Human cancers have been extensively profiled by
transcriptomic- and miRNA-based studies and increasingly
by metabolic profiling, owing to recent advances in
metabolomic platforms. Efforts to integrate these multilevel events to form gene-metabolite networks have led to
a better understanding of the molecular basis of cancer. In
the current study, to decipher the mechanism underlying
aberrant glucose metabolism induced by dietary ZD in the
earliest stage of esophageal carcinogenesis, we performed
an integrated analysis of metabolomics with our published
transcriptomics for preneoplastic ZD rat esophagus [16].
This analysis uncovers a direct link between glucose
down-regulation and up-regulation of the glycolytic
enzyme HK2 (Figure 2). HK2 catalyzes the first step of
glycolysis and is overexpressed in many human cancers,
including ESCC. Several other enzymes in glycolysis are
also increased in cancer cells, but unlike HK2 they are
also expressed in normal cells [58]. Genetic deletion of
HK2 has been reported to reduce the overall tumor burden
in lungs in a genetic mouse lung cancer model, indicating
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Rat studies
The Animal protocol was approved by the Thomas
Jefferson University Animal Care and Use Committee.
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Statistical analysis

Male weanling Sprague-Dawley rats (50 ± 5 g) were
obtained from Taconic Laboratory (Germantown, NY).
Custom-formulated ZD and ZS diets (Harlan Teklad,
Madison, WI) were identical except for the amount of
zinc, which was 3-4 ppm for ZD and ~60 ppm for ZS
diet. Weanling male rats (n = 48) were fed a ZD (n = 32)
or ZS (n = 16) diet for 6 weeks to establish esophageal
proliferation in ZD rats [16, 20, 27]. ZD rats were fed
ad libitum and ZS rats were pair-fed to ZD animals to
match the decreased food consumption of ZD rats [16,
20, 27]. After 6 weeks ZD rats evidenced increased cell
proliferation in the esophagus, as assessed by increased
expression of proliferating cell nuclear antigen PCNA
[15]. Zinc gluconate (1.0 mg elemental zinc) in saline was
then administered intragastrically to 16 ZD rats, which
were immediately switched to the ZS diet to form the
ZR group. At 72 hours after replenishment, all animals
(ZD, ZR, and ZS, n = 16 rats/group) were killed. Whole
esophagus was excised and collected onto ice to minimize
further metabolism. Esophageal epithelia (n = 10 rats/
group) were prepared by using a blade to remove the
submucosal and muscularis layers, snap-frozen in liquid
nitrogen, and stored at -80oC [16, 64]. The remaining
esophageal samples were fixed in 10% buffered formalin
and paraffin embedded.

For analysis involving only 2 sets of data, a student’s
t-test or welch t-test was used depending on a F-test for
differences in variance. For analysis involving multiple
comparisons of all 3 groups (ZD, ZS and ZR), a ShapiroWilk Normality test was performed for each group. If any
group failed the normality test, an overall Kruskal-Wallis
chi-squared test was performed to test if there were any
differences among the groups. A significant Kruskal-Wallis
result was followed by pairwise Wilcoxon rank sum test to
identify the differences between individual groups. In the
case where no group failed the normality test, the Levene’s
homogeneity of variance test was performed. For datasets
that were homoscedastic, a standard one-way ANOVA for
overall differences was performed, followed by the Tukey
HSD pot-hoc t-test for determination of differences among
the groups. For heteroscedastic data, a Welch one-way
ANOVA was performed, followed by the Games-Howell
post hoc t-test for determination of differences among the
groups. Statistical tests were 2-sided and were considered
significant at P≤0.05. Statistical analysis was performed
using R (http://www.R-project.org).

Metabolome network visualization

GC TOF MS data acquisition and processing

Network analysis was used to investigate statistical
and multivariate modeling results within a biochemical
context. A biochemical and chemical similarity network
[45] was calculated for all measured metabolites with
KEGG [46] and PubChem CIDs [47]. Enzymatic
interactions were determined based on product-precursor
relationships defined in the KEGG RPAIR database.
Molecules not directly participating in biochemical
transformations, but sharing many structural properties,
based on PubChem Substructure Fingerprints [66], were
connected at a threshold of Tanimoto similarity coefficient
≥ 0.7.
The table of metabolites (nodes) and network
properties (p-values, direction of change) provided by
MetaMapp were imported into the Cytoscape software and
networks were generated by the organic layout algorithm
in Cytoscape. Red and blue nodes show the increase and
decrease in the amounts of metabolites, respectively.
The blue lines reflect chemical similarity and red lines
show biochemical reactions. Labels are not shown for
metabolites that did not pass significance tests.

For metabolomic profiling, frozen esophageal
samples from ZD, ZS, and ZR rats (n = 8 rats per group;
20 mg per esophagus) were shipped on dry ice to the
NIH West Coast Metabolomics Center, University of
California, Davis. Esophageal tissue was extracted and
derivatized as described [40, 42]. For primary metabolites
analysis by GC-TOF MS, the cold injection/automatic
liner exchange gas chromatography-time of flight mass
spectrometry (CIS-ALEX GC-TOF MS, Leco Pegasus
IV) was employed using chromatographic and mass
spectrometric parameters as previously described [40,
42]. From around 800 individual peaks detected per
chromatogram, 353 genuine metabolites remained after
extensive cleanup and filtering through the BinBase
metabolomic database. Using the Fiehnlib libraries
of over 1,200 mass spectra and retention indices for
identified metabolites, 155 compounds per studies were
be structurally identified by matching mass spectra and
retention indices to authentic standards (MSI [65] level
1 identifications) or annotated by very high mass spectral
similarities to the NIST14 library and close retention time
predictions (MSI level 2 identifications, name followed by
the label “NIST” in the Tables 1 and 2). A quality control
sample for extracts was prepared by mixing small biofluid
(~5 μl) of each sample in a study set, thus providing a
sample with the true representation of the breadth of
metabolites present in the sample set.
www.impactjournals.com/oncotarget

Integrating metabolomics with gene expression
data
A genomics/metabolomics integration network from
the data the metabolic profile in ZD rat esophagus was
integrated with our published transcriptome dataset for this
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tissue ( > 2300 dysregulated genes, identical study design
as metabolomics data) [16]. The network contains genes,
proteins and metabolites. It was queried from significant
genes and metabolites (P-value < 0.05) and mapped with
log2 fold-change.

above 35 were excluded from analysis.

Human ESCC samples
Twelve cases of FFPE human ESCC samples were
obtained from Thomas Jefferson University Hospital
(Philadelphia, PA).

Integrating gene expression data with miRNA
profiling data

In situ hybridization

To find known miRNAs that regulate HK2, we
searched our published miRNA profiling data for ZD
esophagus [28].

miRCURY locked nucleic acid (LNA)™ microRNA
detection probes, namely, hsa-miR-143, rno-miR-31, and
negative controls were purchased from Exiqon (Vedbaek,
Denmark). The oligonucleotides are double DIG-labeled
at the 5’- and 3’-ends. ISH was performed on 6 µm FFPE
sections as previously described [26-28]. Following
deparaffinization, rehydration in graded alcohol and
proteinase K treatment, tissue sections were hybridized
with miR-143 probe (20 nM), in hybridization buffer
(Exiqon) at 57oC for 14 h in a hybridizer (Dako, Glostrup,
Denmark). Following stringent washes in SSC buffers,
the sections were blocked against unspecific binding of
the detecting antibody, using DIG wash and blocking
reagent. miRNA was localized by incubation with
4-nitro-blue tetrazolium (NBT) and 5-brom-4-chloro-3′indolylphosphate (BCIP) (Roche, Mannheim, Germany).
Nuclear fast red (Vector Lab., Burlingname, CA) was used
as a counterstain.

Rat esophageal samples for qPCR, TaqMan
miRNA assay, ISH & IHC assays
For analyses involving 6 wks-ZD esophagus,
esophageal tissues from the current metabolomic profiling
study were used. For analyses involving esophageal
tumor endpoint, archived samples of ESCC-bearing ZD
esophagus and tumor-free control ZS esophagus from a
previous study [28] were employed.

RNA isolation
Esophageal epithelial samples frozen in liquid
nitrogen were pulverized to a fine powder using a chilled
hammer. Total RNA was extracted from the pulverized
samples using an animal tissue RNA extraction Kit
(#25700, Norgen Biotek, Ontario, Canada). RNA
concentration of each sample was determined using a
NanoDrop 1000 (Thermo Scientific). All RNA samples
displayed a 260:280 ratio > 1.8, and a 260:230 ratio > 1.8.

Immunohistochemistry (IHC)
FFPE tissues were deparaffinized, and rehydrated
in graded alcohols. IHC was carried out as previously
described [20, 27], using anti-hexokinase 2 antibody
[3D3] (#NBP1-51643, mouse monoclonal, Novus
Biologicals, Littleton, CO, USA) and PCNA antibody
(clone PC-10, Ab-1, Thermo Scientific, Waltham, MA,
USA), after citrate-based antigen retrieval. Protein was
localized by incubation with 3-amino-9-ethylcarbazole
substrate-chromogen (Dako, Carpinteria, CA, USA) or
3,3’-diaminobenzidine tetrahydrochloride (Sigma-Aldrich,
St Louis, MO, USA).

qPCR
cDNA was reverse transcribed using the HighCapacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA) according to the manufacturer’s protocol.
qPCR was performed using pre-designed probes (Applied
Biosystems), Psmb6 and Oaz1 as the normalizers, and the
comparative Ct method.

Microscopy

TaqMan miRNA assay

IHC and ISH analyses were performed by light
microscopy using an Olympus BX51 microscope and
photographs taken with a Spot RT3 camera and Spot
software v. 4.6.

Reverse transcription of miRNAs was performed
according to the manufacturer’s instructions (Applied
Biosystems, Foster City, CA) with a reaction volume of
15 μl containing 350 ng of total RNA. Real-time qPCR
was performed using StepOnePlus Real-time System
(Applied Biosystems). Each miRNA and endogenous
control (snoRNA and U87) was measured in triplicates.
As an overall quality control, Ct (cycle threshold) values
www.impactjournals.com/oncotarget

Zn content analysis
Serum Zn content is determined by atomic
absorption spectrometry [16].
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